The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
A small molecule–kinase interaction map for clinical kinase inhibitors
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Keys, J. R., Land vatter, S. W., et al. (1994) · Nature · doi:10.1038/372739a0 · Cited by 3,288
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251194298 · Cited by 2,558
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 1×
“Compounds must be tested experimentally against many kinases to assess molecular specificity and to identify off-target interaction”
Backgroundp38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases
Kumar, S., Boehm, J., & Lee, J. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1177 · Cited by 1,197
BindingDB (2025) · PubMed · doi:10.7270/q2pc374f · Cited by 924
Nagar, B., Bornmann, W. G., Pellicena, P., Schindler, T. H., Veach, D. R., Miller, W. T., Clarkson, B. D., & Kuriyan, J. (2002) · PubMed · Cited by 923
Wood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 845
BindingDB (2025) · PubMed · doi:10.7270/q2dr317m · Cited by 843
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb770 · Cited by 833
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
Gray, N. S., Wodicka, L., Thunnissen, A.-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., et al. (1998) · Science · doi:10.1126/science.281.5376.533 · Cited by 808
Self-citationWedge, S. R., Ogilvie, D., Dukes, M., Kendrew, J., Chester, R., Jackson, J. A., Boffey, S. J., Valentine, P. J., Curwen, J., Musgrove, H. L., et al. (2002) · PubMed · Cited by 798
Rusnak, D. W., Lackey, K. E., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J., et al. (2001) · PubMed · Cited by 728
Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K. P., & Hughes, T. P. (2002) · Blood · doi:10.1182/blood.v99.9.3472 · Cited by 649
Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL
Azam, M., Latek, R. R., & Daley, G. Q. (2003) · Cell · doi:10.1016/s0092-8674(03)00190-9 · Cited by 613
Issues and progress with protein kinase inhibitors for cancer treatment
Dancey, J., & Sausville, E. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1066 · Cited by 526
Combinatorial chemoprevention of intestinal neoplasia
Torrance, C. J., Jackson, P. E., Montgomery, E., Kinzler, K. W., Vogelstein, B., Wissner, A., Nunes, M., Frost, P., & Discafani, C. M. (2000) · Nature Medicine · doi:10.1038/79534 · Cited by 493
von Bubnoff, N., Schneller, F., Peschel, C., & Duyster, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07679-1 · Cited by 464
Ma, Y., Zeng, S., Metcalfe, D. D., Akin, C., Dimitrijevic, S., Butterfield, J. H., McMahon, G., & Longley, B. J. (2002) · Blood · doi:10.1182/blood.v99.5.1741 · Cited by 449
A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket
Tong, L., Pav, S., White, D. M., Rogers, S., Crane, K. M., Cywin, C. L., Brown, M. L., & Pargellis, C. A. (1997) · Nature Structural Biology · doi:10.1038/nsb0497-311 · Cited by 387
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
Gambacorti-Passerini, C. B., Gunby, R. H., Piazza, R., Galietta, A., Rostagno, R., & Scapozza, L. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)00979-3 · Cited by 373
An efficient proteomics method to identify the cellular targets of protein kinase inhibitors
Godl, K., Wissing, J., Kurtenbach, A., Habenberger, P., Blencke, S., Gutbrod, H., Salassidis, K., Stein-Gerlach, M., Missio, A., Cotten, M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2535024100 · Cited by 336
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
Kelly, L. M., Yu, J.-C., Boulton, C. L., Apatira, M., Li, J., Sullivan, C. M., Williams, I., Amaral, S. M., Curley, D. P., Duclos, N., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00070-3 · Cited by 305
Meggio, F., Deana, A. D., Ruzzene, M., Brunati, A. M., Cesaro, L., Guerra, B., Meyer, T., Mett, H., Fabbro, D., Furet, P., et al. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.317_c.x · Cited by 296
Perspectives on the development of a molecularly targeted agent
Druker, B. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00025-9 · Cited by 273
Roumiantsev, S., Shah, N. P., Gorre, M. E., Nicoll, J., Brasher, B. B., Sawyers, C. L., & Van Etten, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162140299 · Cited by 253
Rosée, P. G. L., Corbin, A. S., Stoffregen, E. P., Deininger, M. W., & Druker, B. J. (2002) · PubMed · Cited by 203
Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity
Fitzgerald, C. E., Patel, S. B., Becker, J. W., Cameron, P. M., Zaller, D., Pikounis, V. B., O'Keefe, S. J., & Scapin, G. (2003) · Nature Structural & Molecular Biology · doi:10.1038/nsb949 · Cited by 182
Kinomics—structural biology and chemogenomics of kinase inhibitors and targets
Vieth, M., Higgs, R. E., Robertson, D. H., Shapiro, M., Gragg, E. A., & Hemmerle, H. (2004) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.11.028 · Cited by 175
Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo
Dietz, A. B., Souan, L., Knutson, G. J., Bulur, P. A., Litzow, M. R., & Vuk-Pavlović, S. (2004) · Blood · doi:10.1182/blood-2003-12-4266 · Cited by 166
Display cloning: functional identification of natural product receptors using cDNA-phage display
Sche, P. P., McKenzie, K. M., White, J. D., & Austin, D. J. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(00)80018-6 · Cited by 135
Warmuth, M., Simon, N., Mitina, O., Mathes, R., Fabbro, D., Manley, P. W., Buchdunger, E., Forster, K., Moarefi, I., & Hallek, M. J. (2002) · Blood · doi:10.1182/blood-2002-01-0288 · Cited by 134
Allen, L. F., Lenehan, P. F., Eiseman, I. A., Elliott, W. L., & Fry, D. J. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70122-x · Cited by 127
Huron, D. R., Gorre, M. E., Kraker, A. J., Sawyers, C. L., Rosen, N. X., & Moasser, M. M. (2003) · PubMed · Cited by 118
Bcr-Abl inhibition as a modality of CML therapeutics
Buchdunger, E., Matter, A., & Druker, B. J. (2001) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(01)00022-1 · Cited by 102
Mattiuzzi, G. N., Cortes, J. E., Talpaz, M., Reuben, J. M., Rios, M. B., Shan, J., Kontoyiannis, D. P., Giles, F. J., RAAD, I. I., Verstovšek, S., et al. (2003) · PubMed · Cited by 101
Allen, L. F., Lenehan, P. F., Eiseman, I. A., et al. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.34049 · Cited by 71
Novel Agents in the Treatment of Lung Cancer
Lynch, T. J., Adjei, A. A., Bunn, P. A., DuBois, R. N., Gandara, D. R., Giaccone, G., Govindan, R., Herbst, R. S., Johnson, B. E., Khuri, F. R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040021 · Cited by 24
Cited by
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and Promises
Armulik, A., Genové, G., & Betsholtz, C. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.07.001 · Cited by 2,653
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Metadata
- Authors
- Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., Ford, J. M., Galvin, M., Gerlach, J. L., Grotzfeld, R. M., Herrgard, S., Insko, D. E., Insko, M. A., Lai, A. G., Lélias, J.-M., Mehta, S. A., Milanov, Z. V., Velasco, A. M., Wodicka, L. M., Patel, H. K., Zarrinkar, P. P., & Lockhart, D. J.
- Venue
- Nature Biotechnology
- Published
- 2005-02-13
- Volume
- 23
- Issue
- 3
- Pages
- 329-336
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2014582878
- Cited by
- 1,892
- References
- 47
- FWCI
- 117.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.